NASDAQ$HOWL

Werewolf Therapeutics Inc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Headline financials

Total Revenue

$5.9M

Previous: $384K+1435.7%
EPS (adj)

-$0.23

Previous: -$0.40+42.5%
Capital Expenditures

-$221K

Previous: -$3.09M+92.9%
Free Cash Flow

-$7.43M

Previous: -$15M+50.6%
Net Income

-$8.29M

Previous: -$11.9M+30.6%
Operating Income

-$9.25M

Previous: -$12.5M+26.2%
Gross Profit

$5.45M

Previous: $384K+1319.8%
Cash & Equivalents

$130M

Previous: $140M-7.2%
Total Assets

$176M

Previous: $172M+2.3%
R&D Expense

$10.8M

No prior period
Stock-Based Comp

$2.1M

Previous: $1.94M+8.3%

Revenue & EPS history

Werewolf Therapeutics · Revenue · Quarterly

$5.9M

Q3 2023+1,435.7%vs Q3 2022
Beat estimate in 4 of 12 quarters(33%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

+0.1%

Avg return

Earnings day

-0.8%

Avg return

5 days after

+2.2%

Avg return

30 days after

52%

12 / 23 earnings

Positive

+16.5%

Q2 2022

Best reaction

-7.4%

Q4 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-3.5%-2.3%-39.8%
Q3 2025-5.0%-7.4%-22.0%
Q2 2025-1.5%-5.9%+5.9%
Q1 2025+0.9%-2.7%+9.9%
Q4 2024-0.9%-3.4%-21.5%
Q3 2024-5.7%-11.9%-26.2%
Q1 2024-1.6%-9.9%-15.0%
Q4 2023-7.4%-6.1%-15.8%
Q3 2023-0.9%+3.6%+28.8%
Q2 2023+3.2%-0.8%-0.4%
Q1 2023-3.3%-9.9%+11.2%
Q4 2022+6.1%+9.2%+3.1%
Q3 2022+2.3%-5.0%-19.4%
Q2 2022+16.5%+21.3%+55.2%
Q1 2022+3.3%-12.1%+1.7%
Q4 2021+0.5%+9.5%+12.6%
Q3 2021+1.8%+1.6%-6.7%
Q3 2020+1.8%+1.6%-6.7%
Q2 2021-3.5%-2.7%+13.9%
Q2 2020-3.5%-2.7%+13.9%
Q1 2021+1.0%+5.8%+22.4%
Q1 2020+1.0%+5.8%+22.4%
Q4 2020+1.0%+5.8%+22.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro